Table 3.

Treatment-related Adverse Events occurring in >2 patients, highest grade per patient

	Dose-level 1 (n = 3)				Dose-level 2 (n = 25)				Dose-level 3 (n = 8)				Total (N = 36)
GSK3052230	10 mg/kg				15 mg/kg				20 mg/kg
Adverse Event, (n %)	Grade 1/2		Grade 3		Grade 1/2		Grade 3		Grade 1/2		Grade 3
Nausea	2	(67%)			11	(44%)	1	(4%)	6	(75%)			20 (56%)
Decreased appetite	3	(100%)			7	(28%)			3	(38%)			13 (36%)
Infusion related reaction	1	(33%)			6	(24%)	1	(4%)	3	(38%)	2	(25%)	13 (36%)
Neutrophil count decreased	1	(33%)	1	(33%)	3	(12%)	6	(24%)			2	(26%)	13 (36%)
Fatigue	1	(33%)			7	(28%)			4	(50%)			12 (33%)
Asthenia	0				5	(20%)	1	(4%)	3	(38%)			9 (25%)
Blood creatinine increased	1	(33%)			6	(24%)			2	(25%)			9 (25%)
Vomiting	1	(33%)			4	(16%)	1	(4%)	3	(38%)			9 (25%)
Anemia	1	(33%)			4	(16%)	2	(8%)	0				7 (19%)
Peripheral sensory neuropathy	1	(33%)			6	(24%)			0				7 (19%)
Dysgeusia	1	(33%)			3	(12%)			2	(25%)			6 (17%)
Hypertension	0				4	(16%)			1	(13%)	1	(13%)	6 (17%)
Lacrimation increased	2	(67%)			4	(16%)			0				6 (17%)
Diarrhea	1	(33%)			1	(4%)	1	(4%)	1	(13%)			4 (11%)
Hiccups	0				3	(12%)			1	(13%)			4 (11%)
Leukopenia	0				4	(16%)			0				4 (11%)
Tinnitus	1	(33%)			2	(8%)			1	(13%)			4 (11%)
Abdominal pain upper	0				3	(12%)	1	(4%)	0				3 (8%)
ALT increased					3	(12%)							3 (8%)
Alopecia	0				3	(12%)			0				3 (8%)
AST increased	0				3	(12%)			0				3 (8%)
Constipation	0				2	(8%)			1	(13%)			3 (8%)
Hypoesthesia	0				2	(8%)			1	(13%)			3 (8%)
Mucosal inflammation	0				2	(8%)			1	(13%)			3 (8%)
Paresthesia	0				3	(12%)			0				3 (8%)
Rash	1	(33%)			2	(8%)			1	(13%)			3 (8%)
Weight decreased	0				2	(8%)			1	(13%)			3 (8%)

Abbreviations: ALT Alanine aminotransferase, AST Aspartate aminotransferase